AstraZeneca reported positive Phase III results for baxdrostat, an aldosterone synthase inhibitor targeting uncontrolled and treatment-resistant hypertension. The trial met all primary and secondary endpoints, demonstrating statistically significant blood pressure reductions. This success validates AstraZeneca's $1.8 billion acquisition of CinCor Pharma in 2023. The oral drug showed a favorable safety profile and efficacy across patient subgroups. AstraZeneca projects baxdrostat as a potential multi-billion-dollar product, addressing an unmet need with a novel mechanism distinct from existing therapies. Detailed data are expected to be presented at upcoming medical congresses.